Parker Waichman Applauds NBC Nightly News Coverage Featuring Firm Client Diane Wirth and Highlighting GLP-1 Vision Loss and NAION

Hundreds of lawsuits alleging that GLP-1 medicines, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, caused NAION-related permanent vision loss have been centralized in federal MDL No. 3163. The plaintiff law firm says scientific and regulatory scrutiny of the alleged link is growing and claims manufacturers failed to provide adequate warnings, while manufacturers dispute causation and warning-deficiency allegations. The developing litigation presents a potential legal, regulatory and reputational risk for major GLP-1 drug manufacturers, although the release provides no quantified damages or judicial ruling.

Analysis

This is plaintiff-side publicity rather than new clinical, regulatory, or adjudicated evidence, so it should not independently change GLP-1 earnings estimates. The relevant equity risk for Novo Nordisk (NVO) and Eli Lilly (LLY) is not damages near term, but a label-change or prescriber-behavior feedback loop: even a low-incidence vision warning could reduce persistence, raise discontinuation rates, and shift marketing spend toward risk communication. That would matter more for NVO, where obesity-franchise growth and competitive share defense leave less room for an avoidable demand-friction narrative; LLY's supply-constrained demand and broader product cycle provide a relatively stronger cushion.

Over the next 1-3 months, the only material catalysts are an FDA/EMA safety communication, a manufacturer label revision, publication of a large adjusted real-world study, or an MDL ruling that materially strengthens discovery leverage. In the absence of one, headline-driven weakness is likely transitory because NAION has substantial baseline risk-factor overlap with diabetes, obesity, hypertension, sleep apnea, and age—making causation and damages quantification more difficult than the publicity suggests. The contrarian risk is underappreciated: a formal warning could create a class-wide utilization impact well before ultimate litigation costs are known, especially among primary-care prescribers and telehealth weight-loss channels.

Key Decisions for Investors

• No standalone litigation trade on this release. Treat it as an alert only; require an FDA/EMA action, peer-reviewed causal evidence, or MDL discovery ruling before revising NVO or LLY liability assumptions.
• Maintain a relative preference for LLY over NVO for the next 1-3 months if GLP-1 safety headlines intensify: long LLY / short NVO in equal beta-adjusted dollars. Thesis is that NVO faces greater multiple sensitivity to incremental obesity-demand friction; exit if NVO's weekly prescription/share data remain resilient or if LLY receives equivalent labeling pressure.
• Set event alerts for any NAION label language, prescribing-information update, or regulator safety review. A formal class warning would justify reducing obesity-exposure risk immediately, with NVO most vulnerable to a 5-10% multiple de-rating even before sales estimates move.
• Monitor quarterly discontinuation rates, obesity new-start trends, and direct-to-consumer marketing commentary from both companies. A sustained increase in discontinuations or a guidance revision—not lawsuit count—would falsify the view that this remains reputational noise rather than a demand impairment.